Vorinostat

Generic Name: Vorinostat

Brand Names: Zolinza

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₂₀N_₂O_₃

CAS Number: 149647-78-9

Unique Ingredient Identifier: 58IFB293JI

Background: Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...

Indication: 用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。

Associated Conditions: Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma

Associated Therapies: -

Clinical Trials

Phase I Study of Vorinostat and Sorafenib in Advanced Cancer

Phase 1

Completed

Conditions: Malignant Solid Tumour
Renal Cell Carcinoma
Non Small Cell Lung Carcinoma

Interventions: Drug: Sorafenib
Drug: Vorinostat

First Posted Date: 2008-03-14

Last Posted Date: 2013-06-20

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 36

Registration Number: NCT00635791

Locations: 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)

Phase 1

Completed

Conditions: Advanced Cancer Relapsed
Advanced Cancer Refractory

Interventions: Drug: vorinostat

First Posted Date: 2008-03-11

Last Posted Date: 2015-07-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 25

Registration Number: NCT00632931

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Other: placebo
Drug: vorinostat

First Posted Date: 2008-02-15

Last Posted Date: 2024-02-07

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 68

Registration Number: NCT00616967

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Indiana University Purdue University of Indianapolis, Indianapolis, Indiana, United States

and more 2 locations

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Phase 1

Completed

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma

Interventions: Drug: vorinostat
Biological: rituximab
Drug: ifosfamide
Drug: carboplatin
Drug: etoposide
Other: pharmacological study
Other: laboratory biomarker analysis
Genetic: gene expression analysis

First Posted Date: 2008-01-28

Last Posted Date: 2017-05-25

Lead Sponsor: University of Washington

Target Recruit Count: 29

Registration Number: NCT00601718

Locations: 🇺🇸
Puget Sound Oncology Consortium, Seattle, Washington, United States

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

Phase 2

Completed

Conditions: Stage III Prostate Cancer
Prostate Adenocarcinoma
Stage I Prostate Cancer
Stage IIA Prostate Cancer
Stage IIB Prostate Cancer

Interventions: Drug: Bicalutamide
Drug: Goserelin Acetate
Other: Laboratory Biomarker Analysis
Drug: Leuprolide Acetate
Procedure: Therapeutic Conventional Surgery
Drug: Vorinostat

First Posted Date: 2008-01-09

Last Posted Date: 2017-10-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00589472

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCSF Medical Center-Parnassus, San Francisco, California, United States

and more 12 locations

Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Vorinostat
Drug: Paclitaxel
Drug: Trastuzumab
Drug: Doxorubicin
Drug: Cyclophosphamide
Procedure: Surgery

First Posted Date: 2007-12-17

Last Posted Date: 2020-10-14

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 55

Registration Number: NCT00574587

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Small Intestine Cancer

Interventions: Drug: vorinostat
Other: Correlative studies

First Posted Date: 2007-11-21

Last Posted Date: 2015-07-16

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 23

Registration Number: NCT00561418

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)

Phase 1

Terminated

Conditions: Glioblastoma Multiforme
Anaplastic Glioma

Interventions: Procedure: Surgical Resection
Drug: Vorinostat
Drug: Isotretinoin
Drug: Temozolomide

First Posted Date: 2007-11-08

Last Posted Date: 2024-08-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 55

Registration Number: NCT00555399

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer

Phase 1

Completed

Conditions: Esophageal Cancer
Gastric Cancer
Liver Cancer

First Posted Date: 2007-09-28

Last Posted Date: 2013-06-28

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 23

Registration Number: NCT00537121

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

Phase 1

Completed

Conditions: Adult Grade III Lymphomatoid Granulomatosis
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Intraocular Lymphoma
Nodal Marginal Zone B-cell Lymphoma
Primary Central Nervous System Non-Hodgkin Lymphoma
Recurrent Adult Burkitt Lymphoma

Interventions: Drug: vorinostat
Other: pharmacological study

First Posted Date: 2007-07-11

Last Posted Date: 2014-02-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00499811

Locations: 🇺🇸
West Virginia University Healthcare, Morgantown, West Virginia, United States
🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy